A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03981822

Acronym

CARE-1

Enrollment

105

Registered

2019-06-11

Start date

2019-06-25

Completion date

2020-07-08

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condylomata Acuminata, Papillomavirus Infections, Sexually Transmitted Diseases, Sexually Transmitted Diseases, Viral, Skin Diseases, Skin Diseases, Infectious, Skin Diseases, Viral, Warts

Keywords

Human Papilloma Virus (HPV), Genital Warts, Sexually Transmitted Disease (STD), Viral Disease

Brief summary

This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW). This study is divided into two parts (Part A and Part B). Increasing durations of skin exposure to study drug (VP-102 or placebo) will be evaluated in three treatment groups prior to progressing to enrollment in Part B. Part A & B will enroll a approximately 108 subjects completing 4 treatment applications every 21 days and continuing with follow-up assessments at Day 84, 112 and 147.

Detailed description

This study is to determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. It is divided into two parts (Part A and Part B). The aim of Part A is to determine the two best treatment regimens for evaluation of safety and efficacy in Part B.In Part A, Study drug (VP-102 or placebo) will be administered once every 21 days for up to four applications. Enrollment will begin in Group 1, then proceed into Group 2, and lastly into Group 3. A safety review will be conducted to determine whether enrollment can be initiated into the next Group. An additional blinded safety review will be performed after all six subjects in Group 3 have completed the 48-hour Visit, in order to support dose selection for Part B (Safety and Efficacy). Part B of the study will begin enrollment only after the Sponsor has selected the two dose regimens from Part A. The study will remain blinded until completion of both parts of the study. In Part A, up to 18 subjects will be randomized to VP-102 or placebo treatment with three different regimens. When Part B is open an additional \ 90 subjects will be enrolled and randomized to VP-102 or placebo with two treatment regimens. Two of the treatment arms will be VP-102 Regimen 1 and VP-102 Regimen 2. The other two treatment arms will be placebo (Placebo Regimen 1 and Placebo Regimen 2), with corresponding durations of skin exposure matching those selected for VP-102 Regimen 1 and Regimen 2. As an example, if the regimens selected from Part A are the 2-hour and 6-hour applications of VP-102, then VP-102 Regimen 1 would be VP-102 treatment for 2-hours and VP-102 Regimen 2 would be VP-102 treatment for 6-hours. Likewise, Placebo Regimen 1 would be placebo treatment for 2 hours and Placebo Regimen 2 would be placebo treatment for 6-hours. Randomization of the four treatment arms (VP-102 Regimen 1:VP-102 Regimen 2:Placebo Regimen 1:Placebo Regimen 2) will be 3:3:2:2. In both Regimen 1 and Regimen 2, study drug will be administered to EGW once every 21 days for up to four applications. Subjects will be asked to remove the study drug at the designated time selected from the dose regimen findings in Part A of the study. Treatment will continue with a minimum of every 21 days, until complete clearance or a maximum of four treatment sessions. Safety assessments including recording of local skin reactions are conducted at each treatment visit and at follow up visits Day 84, 112, and 147.

Interventions

COMBINATION_PRODUCTVP-102 and applicator

In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.

COMBINATION_PRODUCTPlacebo

The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Double-blind

Intervention model description

The aim of Part A is to determine the two best treatment regimens for evaluation of safety and efficacy in Part B. Increasing durations of skin exposure to study drug (VP-102 or placebo) will be evaluated in three treatment groups (n=6/group) that will enroll progressively. Part B of the study will begin enrollment only after the Sponsor has selected the two dose regimens in Part A, which will be called VP-102 Regimen 1 and Regimen 2.Approximately 90 subjects will be enrolled and randomized to one of four treatment arms (two treatment regimens, each with VP-102 and Placebo). Randomization will be stratified by sex so that neither gender exceeds \ 60% of any treatment arm. Two of the treatment arms will be VP-102 Regimen 1 and VP-102 Regimen 2. The other two treatment arms will be placebo (Placebo Regimen 1 and Placebo Regimen 2), with corresponding durations of skin exposure matching those selected for VP-102 Regimen 1 and Regimen 2.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * Be healthy, immunocompetent males or females ≥ 18 years of age * Present with ≥ 2 and ≤ 30 external genital and/or perianal warts in ≥ 1 of the following anatomic areas: * In both sexes: medial thigh (except inguinal fold); supra-pubic, perineal, and perianal areas * In men: over the glans penis (excluding urethral meatus), penis shaft, scrotum, and foreskin * In women: vulva (excluding labia minora and mucosal surfaces) * Have warts present for ≥ 4 weeks at the baseline visit * Have warts that are ≤ 8 mm in diameter each Key

Exclusion criteria

* Have a wart within the allowed treatment area \> 8 mm in diameter or with an eroded or ulcerated surface, in the Investigator's opinion * Have an unclear diagnosis of condyloma * Have any wart types other than genital warts (e.g., common or plantar warts) that require treatment during the study period * Have active genital herpes eruption, or had active genital herpes lesions within 4 weeks before enrollment * Have a history of neoplasia or other HPV-associated malignancies within the last 5 years * Are systemically immunosuppressed * Are sexually active or may become sexually active and are unwilling to practice responsible birth control methods * Are pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.	Compares baseline wart count to Day 84, end of treatment.	Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the Study Day 84 EOT Visit.

Secondary

Measure	Time frame	Description
Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.	Proportion of subjects exhibiting 90% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).
Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Clearance compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.	Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).
Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Compared from baseline to each study visit, treatment 2, (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.	Proportion of subjects exhibiting 75% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).
Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.	Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). Number of warts present were recorded at each treatment visit as well as follow-up visits. For each post baseline treatment visit, the change in number of warts from baseline was calculated.
Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Percent change from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.	Percent Change from Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).

Other

Measure	Time frame	Description
Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Baseline to Study Day 84, Follow-up Visits at Days 112 and 147 (EOS)	Change from baseline in total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).
Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Baseline to Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Percent Change from baseline in the total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).
Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)	Complete clearance compared from Day 84 to follow-up days 112 and 147.	Proportion of subjects who are clear at all three study visits, Study Day 84 (End of Treatment) Visit and remain clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study).
Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.	Proportion of subjects exhibiting reduction of ≥ 1 treatable wart from baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).

Countries

United States

Participant flow

Recruitment details

2 groups from Part A were to be included in Part B based on Part A analysis.

Pre-assignment details

All subject numbers are based on ITT population. Participants in Part A 6-hour and 24-hour group were also included in Part B subject populations.

Participants by arm

Arm	Count
Part A: VP-102 2-hour VP-102 will be applied for 2-hours and removed. VP-102 is applied every 21 days for 4 treatments.	5
Part A: VP-102 6-hour VP-102 will be applied for 6-hours and removed. VP-102 is applied every 21 days for 4 treatments.	5
Part A: VP-102 24-hour VP-102 will be applied for 24-hours and removed. VP-102 is applied every 21 days for 4 treatments.	5
Part A: Placebo Placebo will be applied for 2-,6- or 12-hours and removed. Placebo is applied every 21 days for 4 treatments.	3
Part B: VP-102 6-hour VP-102 will be applied for 6-hours and removed. VP-102 is applied every 21 days for 4 treatments.	25
Part B: 6-hour-Placebo Placebo will be applied for 6-hours and removed. VP-102 is applied every 21 days for 4 treatments.	23
Part B: VP-102 24-hour VP-102 will be applied for 24-hours and removed. VP-102 is applied every 21 days for 4 treatments.	22
Part B: 24-hour-Placebo Placebo will be applied for 24-hours and removed. VP-102 is applied every 21 days for 4 treatments.	17
Total	105

Withdrawals & dropouts

Period	Reason	FG001	FG002	FG004	FG005	FG006	FG007
Overall Study	COVID-19 Related	0	0	2	1	2	1
Overall Study	Lost to Follow-up	1	1	6	4	4	2
Overall Study	Withdrawal by Subject	1	0	0	1	0	2

Baseline characteristics

Characteristic	Part A: VP-102 2-hour	Part A: VP-102 6-hour	Part A: VP-102 24-hour	Part A: Placebo	Part B: VP-102 6-hour	Part B: 6-hour-Placebo	Part B: VP-102 24-hour	Part B: 24-hour-Placebo	Total
Age, Continuous	34.40 years STANDARD_DEVIATION 9.915	43.00 years STANDARD_DEVIATION 8.246	33.80 years STANDARD_DEVIATION 5.263	32.00 years STANDARD_DEVIATION 3.606	38.12 years STANDARD_DEVIATION 10.138	35.87 years STANDARD_DEVIATION 7.973	34.45 years STANDARD_DEVIATION 7.526	33.88 years STANDARD_DEVIATION 6.47	35.85 years STANDARD_DEVIATION 8.26
Baseline number of treatable external genital warts	7 genital warts STANDARD_DEVIATION 5.568	9.60 genital warts STANDARD_DEVIATION 12.012	13.00 genital warts STANDARD_DEVIATION 8.276	11.67 genital warts STANDARD_DEVIATION 12.423	8.28 genital warts STANDARD_DEVIATION 6.38	5.87 genital warts STANDARD_DEVIATION 3.684	8.68 genital warts STANDARD_DEVIATION 5.489	7.76 genital warts STANDARD_DEVIATION 6.897	8.08 genital warts STANDARD_DEVIATION 6.395
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants	0 Participants	0 Participants	0 Participants	6 Participants	1 Participants	2 Participants	5 Participants	15 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	4 Participants	5 Participants	5 Participants	3 Participants	19 Participants	22 Participants	20 Participants	12 Participants	90 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	2 Participants	0 Participants	1 Participants	0 Participants	6 Participants	8 Participants	1 Participants	6 Participants	24 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	3 Participants
Race (NIH/OMB) White	3 Participants	5 Participants	3 Participants	3 Participants	19 Participants	12 Participants	21 Participants	11 Participants	77 Participants
Region of Enrollment United States	5 participants	5 participants	5 participants	3 participants	25 participants	23 participants	22 participants	17 participants	105 participants
Sex: Female, Male Female	4 Participants	3 Participants	2 Participants	0 Participants	10 Participants	10 Participants	10 Participants	7 Participants	46 Participants
Sex: Female, Male Male	1 Participants	2 Participants	3 Participants	3 Participants	15 Participants	13 Participants	12 Participants	10 Participants	59 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	0 / 29	0 / 22	0 / 28	0 / 20	0 / 5	0 / 1
other Total, other adverse events	29 / 29	15 / 22	28 / 28	9 / 20	5 / 5	0 / 1
serious Total, serious adverse events	1 / 29	1 / 22	0 / 28	1 / 20	0 / 5	0 / 1

Outcome results

Primary

Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.

Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the Study Day 84 EOT Visit.

Time frame: Compares baseline wart count to Day 84, end of treatment.

Population: Part B and A: Intent-to-Treat Population. Part B summary is pooled with its respective treatments from Part A.

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.	Yes	11 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.	No	19 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.	No	23 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.	Yes	1 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.	Yes	9 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.	No	18 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.	Yes	0 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.	No	18 Participants

Comparison: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0048Cochran-Mantel-Haenszel

Comparison: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0075Cochran-Mantel-Haenszel

Secondary

Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). Number of warts present were recorded at each treatment visit as well as follow-up visits. For each post baseline treatment visit, the change in number of warts from baseline was calculated.

Time frame: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

Population: ITT Populations

Arm	Measure	Group	Value (MEAN)	Dispersion
Part B Pooled With Part A: VP-102 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	-4.0 Warts	Standard Deviation 4.95
Part B Pooled With Part A: VP-102 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	-4.4 Warts	Standard Deviation 5.8
Part B Pooled With Part A: VP-102 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	-5.2 Warts	Standard Deviation 4.72
Part B Pooled With Part A: VP-102 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	-6.1 Warts	Standard Deviation 5.24
Part B Pooled With Part A: VP-102 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Day 112	-5.3 Warts	Standard Deviation 5.21
Part B Pooled With Part A: VP-102 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Visit Day 147 EOS	-5.0 Warts	Standard Deviation 7.63
Part B Pooled With Part A: Placebo 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Visit Day 147 EOS	-1.2 Warts	Standard Deviation 5.49
Part B Pooled With Part A: Placebo 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	-1.1 Warts	Standard Deviation 4.92
Part B Pooled With Part A: Placebo 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	-0.3 Warts	Standard Deviation 1.11
Part B Pooled With Part A: Placebo 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	-0.9 Warts	Standard Deviation 3.98
Part B Pooled With Part A: Placebo 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	-1.1 Warts	Standard Deviation 3.69
Part B Pooled With Part A: Placebo 6-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Day 112	-1.1 Warts	Standard Deviation 5.33
Part B Pooled With Part A VP-102 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	-6.3 Warts	Standard Deviation 5.45
Part B Pooled With Part A VP-102 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	-7.1 Warts	Standard Deviation 5.09
Part B Pooled With Part A VP-102 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	-7.4 Warts	Standard Deviation 6.37
Part B Pooled With Part A VP-102 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Visit Day 147 EOS	-7.9 Warts	Standard Deviation 5.46
Part B Pooled With Part A VP-102 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Day 112	-8.1 Warts	Standard Deviation 5.54
Part B Pooled With Part A VP-102 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	-5.3 Warts	Standard Deviation 4.25
Part B Pooled With Part A: Placebo 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Day 112	-0.3 Warts	Standard Deviation 4.39
Part B Pooled With Part A: Placebo 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Visit Day 147 EOS	-0.1 Warts	Standard Deviation 4.66
Part B Pooled With Part A: Placebo 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	-0.5 Warts	Standard Deviation 5.01
Part B Pooled With Part A: Placebo 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	0.1 Warts	Standard Deviation 5.12
Part B Pooled With Part A: Placebo 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	0.6 Warts	Standard Deviation 30.07
Part B Pooled With Part A: Placebo 24-hour	Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	0.5 Warts	Standard Deviation 5.17

Comparison: Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.p-value: 0.002195% CI: [-5.41, -1.24]Mixed Models Analysis

Comparison: Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.p-value: 0.01595% CI: [-5.95, -0.66]Mixed Models Analysis

Comparison: Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.p-value: 0.001195% CI: [-6.54, -1.69]Mixed Models Analysis

Comparison: Study Day 84 EOT Visit: Part B summary is pooled with its respective treatments from Part A.p-value: 0.000795% CI: [-8.25, -2.32]Mixed Models Analysis

Comparison: Follow-up day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.001295% CI: [-7.5, -1.91]Mixed Models Analysis

Comparison: Follow-up visit day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.p-value: 0.034995% CI: [-6.78, -0.26]Mixed Models Analysis

Comparison: Treatment visit 2: Part B summary is pooled with its respective treatments from Part A.p-value: <0.000195% CI: [-7.47, -2.85]Mixed Models Analysis

Comparison: Treatment Visit 3: Degrees of freedom associated with the error term were computed using Kenward-Rogers method.p-value: 0.000595% CI: [-8.37, -2.43]Mixed Models Analysis

Comparison: Treatment visit 4: Part B summary is pooled with its respective treatments from Part A.p-value: <0.000195% CI: [-9.65, -4.12]Mixed Models Analysis

Comparison: Study Day 84 (EOT): Part B summary is pooled with its respective treatments from Part A.p-value: 0.000495% CI: [-9.67, -2.92]Mixed Models Analysis

Comparison: Follow-up day 112: Part B summary is pooled with its respective treatments from Part A.p-value: <0.000195% CI: [-9.89, -3.57]Mixed Models Analysis

Comparison: Follow up day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.p-value: 0.000595% CI: [-10.2, -2.94]Mixed Models Analysis

Secondary

Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Percent Change from Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).

Time frame: Percent change from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

Population: ITT Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part B Pooled With Part A: VP-102 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	-41.4 Wart percentage change from Baseline	Standard Deviation 32.38
Part B Pooled With Part A: VP-102 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	-49.0 Wart percentage change from Baseline	Standard Deviation 37.18
Part B Pooled With Part A: VP-102 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	-65.8 Wart percentage change from Baseline	Standard Deviation 30.69
Part B Pooled With Part A: VP-102 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 End of Treatment Visit	-79.7 Wart percentage change from Baseline	Standard Deviation 34.27
Part B Pooled With Part A: VP-102 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Day 112	-68.2 Wart percentage change from Baseline	Standard Deviation 43.2
Part B Pooled With Part A: VP-102 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Visit Day 147 End of Study	-42.5 Wart percentage change from Baseline	Standard Deviation 111.83
Part B Pooled With Part A: Placebo 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Visit Day 147 End of Study	-6.0 Wart percentage change from Baseline	Standard Deviation 86.56
Part B Pooled With Part A: Placebo 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 End of Treatment Visit	-1.6 Wart percentage change from Baseline	Standard Deviation 78.34
Part B Pooled With Part A: Placebo 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	-6.2 Wart percentage change from Baseline	Standard Deviation 13.14
Part B Pooled With Part A: Placebo 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	-5.1 Wart percentage change from Baseline	Standard Deviation 66.26
Part B Pooled With Part A: Placebo 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	-8.9 Wart percentage change from Baseline	Standard Deviation 44.46
Part B Pooled With Part A: Placebo 6-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Day 112	1.9 Wart percentage change from Baseline	Standard Deviation 91.11
Part B Pooled With Part A VP-102 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	-69.3 Wart percentage change from Baseline	Standard Deviation 34.03
Part B Pooled With Part A VP-102 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	-77.3 Wart percentage change from Baseline	Standard Deviation 26.87
Part B Pooled With Part A VP-102 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 End of Treatment Visit	-77.1 Wart percentage change from Baseline	Standard Deviation 38.66
Part B Pooled With Part A VP-102 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Visit Day 147 End of Study	-79.6 Wart percentage change from Baseline	Standard Deviation 25.01
Part B Pooled With Part A VP-102 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Day 112	-79.2 Wart percentage change from Baseline	Standard Deviation 28.36
Part B Pooled With Part A VP-102 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	-58.5 Wart percentage change from Baseline	Standard Deviation 26.69
Part B Pooled With Part A: Placebo 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Day 112	-14.2 Wart percentage change from Baseline	Standard Deviation 49.6
Part B Pooled With Part A: Placebo 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow up Visit Day 147 End of Study	-12.9 Wart percentage change from Baseline	Standard Deviation 50.49
Part B Pooled With Part A: Placebo 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	-17.8 Wart percentage change from Baseline	Standard Deviation 49.79
Part B Pooled With Part A: Placebo 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 End of Treatment Visit	-5.5 Wart percentage change from Baseline	Standard Deviation 47.98
Part B Pooled With Part A: Placebo 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	-2.6 Wart percentage change from Baseline	Standard Deviation 30.07
Part B Pooled With Part A: Placebo 24-hour	Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	0.6 Wart percentage change from Baseline	Standard Deviation 41.94

Comparison: Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.p-value: <0.000195% CI: [-51.31, -20.87]Mixed Models Analysis

Comparison: Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.p-value: 0.000495% CI: [-66.18, -19.56]Mixed Models Analysis

Comparison: Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.p-value: <0.000195% CI: [-88.15, -35.87]Mixed Models Analysis

Comparison: Study Day 84 End of Treatment Visit: Part B summary is pooled with its respective treatments from Part A.p-value: <0.000195% CI: [-111.44, -49.77]Mixed Models Analysis

Comparison: Follow up Day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.000195% CI: [-103.17, -35.25]Mixed Models Analysis

Comparison: Follow up Visit Day 147 End of Study: Part B summary is pooled with its respective treatments from Part A.p-value: 0.103395% CI: [-90.61, 8.56]Mixed Models Analysis

Comparison: Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.p-value: <0.000195% CI: [-73.26, -39.39]Mixed Models Analysis

Comparison: Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.p-value: <0.000195% CI: [-81.61, -28.8]Mixed Models Analysis

Comparison: Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.p-value: <0.000195% CI: [-107.19, -45.61]Mixed Models Analysis

Comparison: Study Day 84 End of Treatment Visit: Part B summary is pooled with its respective treatments from Part A.p-value: 0.000395% CI: [-102.96, -31.55]Mixed Models Analysis

Comparison: Follow-up Day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.000495% CI: [-110.32, -32.78]Mixed Models Analysis

Comparison: Follow-up Visit Day 147 End of Study: Part B summary is pooled with its respective treatments from Part A.p-value: 0.017895% CI: [-120.82, -11.88]Mixed Models Analysis

Secondary

Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting 75% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).

Time frame: Compared from baseline to each study visit, treatment 2, (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

Population: ITT Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Incidence of >=75% Clearance: YES	5 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Incidence of >=75% Clearance: YES	8 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Incidence of >=75% Clearance: YES	11 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Incidence of >=75% Clearance: YES	15 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Incidence of >=75% Clearance: YES	13 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Incidence of >=75% Clearance: YES	10 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Incidence of >=75% Clearance: YES	4 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Incidence of >=75% Clearance: YES	2 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Incidence of >=75% Clearance: YES	0 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Incidence of >=75% Clearance: YES	2 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Incidence of >=75% Clearance: YES	0 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Incidence of >=75% Clearance: YES	3 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Incidence of >=75% Clearance: YES	14 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Incidence of >=75% Clearance: YES	12 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Incidence of >=75% Clearance: YES	15 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Incidence of >=75% Clearance: YES	13 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Incidence of >=75% Clearance: YES	13 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Incidence of >=75% Clearance: YES	6 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Incidence of >=75% Clearance: YES	3 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Incidence of >=75% Clearance: YES	2 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Incidence of >=75% Clearance: YES	2 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Incidence of >=75% Clearance: YES	2 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Incidence of >=75% Clearance: YES	1 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Incidence of >=75% Clearance: YES	1 Participants

Comparison: Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0356Cochran-Mantel-Haenszel

Comparison: Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.p-value: 0.1477Cochran-Mantel-Haenszel

Comparison: Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0062Cochran-Mantel-Haenszel

Comparison: Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0046Cochran-Mantel-Haenszel

Comparison: Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0177Cochran-Mantel-Haenszel

Comparison: Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0054Cochran-Mantel-Haenszel

Comparison: Study Day 84 (EOT) visit: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0013Cochran-Mantel-Haenszel

Comparison: Study Day 84 (EOT) Visit: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0034Cochran-Mantel-Haenszel

Comparison: Follow-up visit day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0156Cochran-Mantel-Haenszel

Comparison: Follow-up visit day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0367Cochran-Mantel-Haenszel

Comparison: Follow-up visit day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.p-value: 0.1746Cochran-Mantel-Haenszel

Comparison: Follow-up visit day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.p-value: 0.0123Cochran-Mantel-Haenszel

Secondary

Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting 90% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).

Time frame: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

Population: ITT Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Incidence of >=90% Clearance: YES	1 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Incidence of >=90% Clearance: YES	5 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Incidence of >=90% Clearance: YES	7 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Incidence of >=90% Clearance: YES	14 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Incidence of >=90% Clearance: YES	11 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Incidence of >=90% Clearance: YES	9 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Incidence of >=90% Clearance: YES	3 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Incidence of >=90% Clearance: YES	2 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Incidence of >=90% Clearance: YES	0 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Incidence of >=90% Clearance: YES	0 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Incidence of >=90% Clearance: YES	0 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Incidence of >=90% Clearance: YES	2 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Incidence of >=90% Clearance: YES	8 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Incidence of >=90% Clearance: YES	7 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Incidence of >=90% Clearance: YES	11 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Incidence of >=90% Clearance: YES	9 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Incidence of >=90% Clearance: YES	9 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Incidence of >=90% Clearance: YES	4 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Incidence of >=90% Clearance: YES	2 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Incidence of >=90% Clearance: YES	2 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Incidence of >=90% Clearance: YES	2 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Incidence of >=90% Clearance: YES	0 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Incidence of >=90% Clearance: YES	0 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Incidence of >=90% Clearance: YES	0 Participants

Comparison: Treatment Visit 2 Part B summary is pooled with its respective treatments from Part A.p-value: 0.3642Cochran-Mantel-Haenszel

Comparison: Treatment Visit 3 Part B summary is pooled with its respective treatments from Part A.p-value: 0.0356Cochran-Mantel-Haenszel

Comparison: Treatment Visit 4 Part B summary is pooled with its respective treatments from Part A.p-value: 0.0118Cochran-Mantel-Haenszel

Comparison: Study Day84 EOT Part B summary is pooled with its respective treatments from Part A.p-value: 0.0026Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 112 Part B summary is pooled with its respective treatments from Part A.p-value: 0.0174Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 147 EOS Part B summary is pooled with its respective treatments from Part A.p-value: 0.1311Cochran-Mantel-Haenszel

Comparison: Treatment Visit 2 Part B summary is pooled with its respective treatments from Part A.p-value: 0.0967Cochran-Mantel-Haenszel

Comparison: Treatment Visit 3 Part B summary is pooled with its respective treatments from Part A.p-value: 0.1357Cochran-Mantel-Haenszel

Comparison: Treatment Visit 4 Part B summary is pooled with its respective treatments from Part A.p-value: 0.0184Cochran-Mantel-Haenszel

Comparison: Study Day 84 EOT Visit Part B summary is pooled with its respective treatments from Part A.p-value: 0.0024Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 112 Part B summary is pooled with its respective treatments from Part A.p-value: 0.1034Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 147 EOS Part B summary is pooled with its respective treatments from Part A.p-value: 0.1029Cochran-Mantel-Haenszel

Secondary

Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).

Time frame: Clearance compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

Population: Part B and A pooled - ITT population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Yes, Complete Clearance	1 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Yes, Complete Clearance	4 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Yes, Complete Clearance	6 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Yes, Complete Clearance	11 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Yes, Complete Clearance	9 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Yes, Complete Clearance	6 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Yes, Complete Clearance	3 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Yes, Complete Clearance	1 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Yes, Complete Clearance	0 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Yes, Complete Clearance	0 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Yes, Complete Clearance	0 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Yes, Complete Clearance	2 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Yes, Complete Clearance	8 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Yes, Complete Clearance	7 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Yes, Complete Clearance	9 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Yes, Complete Clearance	8 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Yes, Complete Clearance	8 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Yes, Complete Clearance	4 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112: Yes, Complete Clearance	2 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147: Yes, Complete Clearance	2 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3: Yes, Complete Clearance	2 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT: Yes, Complete Clearance	0 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2: Yes, Complete Clearance	0 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4: Yes, Complete Clearance	0 Participants

Comparison: Treatment Visit 2 - Part B summary is pooled with its respective treatments from Part A.p-value: 0.3642Cochran-Mantel-Haenszel

Comparison: Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0967Cochran-Mantel-Haenszel

Comparison: Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0648Cochran-Mantel-Haenszel

Comparison: Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.p-value: 0.1357Cochran-Mantel-Haenszel

Comparison: Treatment Visit 4 Part B summary is pooled with its respective treatments from Part A.p-value: 0.019Cochran-Mantel-Haenszel

Comparison: Treatment Visit 4 Part B summary is pooled with its respective treatments from Part A.p-value: 0.0184Cochran-Mantel-Haenszel

Comparison: Study Day 84 EOT Visit - Part B summary is pooled with its respective treatments from Part A.p-value: 0.0048Cochran-Mantel-Haenszel

Comparison: Study Day 84 EOT Visit - Part B summary is pooled with its respective treatments from Part A.p-value: 0.0075Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 112 - Part B summary is pooled with its respective treatments from Part A.p-value: 0.0539Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 112 - Part B summary is pooled with its respective treatments from Part A.p-value: 0.1638Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 147 EOS - Part B summary is pooled with its respective treatments from Part A.p-value: 0.4766Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 147 EOS - Part B summary is pooled with its respective treatments from Part A.p-value: 0.1588Cochran-Mantel-Haenszel

Other Pre-specified

Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Change from baseline in total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).

Time frame: Baseline to Study Day 84, Follow-up Visits at Days 112 and 147 (EOS)

Population: ITT Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part B Pooled With Part A: VP-102 6-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 (EOT)	-52.60 mm^2	Standard Deviation 67.067
Part B Pooled With Part A: VP-102 6-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Visit Day 147 (EOS)	-59.28 mm^2	Standard Deviation 100.988
Part B Pooled With Part A: VP-102 6-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 112	-79.43 mm^2	Standard Deviation 99.679
Part B Pooled With Part A: Placebo 6-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 (EOT)	-23.64 mm^2	Standard Deviation 59.722
Part B Pooled With Part A: Placebo 6-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Visit Day 147 (EOS)	-6.02 mm^2	Standard Deviation 36.929
Part B Pooled With Part A: Placebo 6-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 112	-20.35 mm^2	Standard Deviation 53.289
Part B Pooled With Part A VP-102 24-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 112	-82.79 mm^2	Standard Deviation 71.75
Part B Pooled With Part A VP-102 24-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 (EOT)	-72.87 mm^2	Standard Deviation 91.659
Part B Pooled With Part A VP-102 24-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Visit Day 147 (EOS)	-68.78 mm^2	Standard Deviation 68.71
Part B Pooled With Part A: Placebo 24-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 (EOT)	1.60 mm^2	Standard Deviation 33.796
Part B Pooled With Part A: Placebo 24-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Visit Day 147 (EOS)	2.21 mm^2	Standard Deviation 45.035
Part B Pooled With Part A: Placebo 24-hour	Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 112	1.40 mm^2	Standard Deviation 39.963

Comparison: Study Day 84 (EOT: Part B summary is pooled with its respective treatments from Part A.p-value: 0.122295% CI: [-76.1, 9.23]Mixed Models Analysis

Comparison: Study Day 112 (EOT: Part B summary is pooled with its respective treatments from Part A.p-value: 0.040395% CI: [-81.3, -1.9]Mixed Models Analysis

Comparison: Follow-up Visit Day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.p-value: 0.086395% CI: [-77.79, 5.33]Mixed Models Analysis

Comparison: Study Day 84 (EOT): Part B summary is pooled with its respective treatments from Part A.p-value: 0.042895% CI: [-100.76, -1.73]Mixed Models Analysis

Comparison: Follow-up Day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.008495% CI: [-110.46, -17]Mixed Models Analysis

Comparison: Follow-up Visit Day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.p-value: 0.027395% CI: [-103.08, -6.35]Mixed Models Analysis

Other Pre-specified

Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Percent Change from baseline in the total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).

Time frame: Baseline to Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Population: ITT Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part B Pooled With Part A: VP-102 6-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 (EOT)	-46.0 Change from baseline in % of wart area	Standard Deviation 52.77
Part B Pooled With Part A: VP-102 6-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 147 (EOS)	-45.8 Change from baseline in % of wart area	Standard Deviation 71.37
Part B Pooled With Part A: VP-102 6-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 112	-48.2 Change from baseline in % of wart area	Standard Deviation 54.67
Part B Pooled With Part A: Placebo 6-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 (EOT)	-22.3 Change from baseline in % of wart area	Standard Deviation 57.92
Part B Pooled With Part A: Placebo 6-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 147 (EOS)	-11.7 Change from baseline in % of wart area	Standard Deviation 52.52
Part B Pooled With Part A: Placebo 6-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 112	-21.5 Change from baseline in % of wart area	Standard Deviation 64.54
Part B Pooled With Part A VP-102 24-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 112	-76.4 Change from baseline in % of wart area	Standard Deviation 12.33
Part B Pooled With Part A VP-102 24-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 (EOT)	-64.2 Change from baseline in % of wart area	Standard Deviation 55.78
Part B Pooled With Part A VP-102 24-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 147 (EOS)	-69.3 Change from baseline in % of wart area	Standard Deviation 16.44
Part B Pooled With Part A: Placebo 24-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 (EOT)	-7.3 Change from baseline in % of wart area	Standard Deviation 93.42
Part B Pooled With Part A: Placebo 24-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 147 (EOS)	19.9 Change from baseline in % of wart area	Standard Deviation 138.49
Part B Pooled With Part A: Placebo 24-hour	Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Follow-up Day 112	13.8 Change from baseline in % of wart area	Standard Deviation 129.61

Comparison: Study Day 84 (EOT): Part B summary is pooled with its respective treatments from Part A.p-value: 0.308395% CI: [-69.96, 22.47]Mixed Models Analysis

Comparison: Follow-up Day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.168695% CI: [-86.93, 15.56]Mixed Models Analysis

Comparison: Follow-up Visit Day 147 End of Study: Part B summary is pooled with its respective treatments from Part A.p-value: 0.238495% CI: [-87.04, 22.1]Mixed Models Analysis

Comparison: Study Day 84 (EOT): Part B summary is pooled with its respective treatments from Part A.p-value: 0.060395% CI: [-103.37, 2.27]Mixed Models Analysis

Comparison: Follow-up Visit Day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.010995% CI: [-138.71, -18.83]Mixed Models Analysis

Comparison: Follow-up Visit Day 147 End of Study: Part B summary is pooled with its respective treatments from Part A.p-value: 0.046795% CI: [-127.64, -0.99]Mixed Models Analysis

Other Pre-specified

Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting reduction of ≥ 1 treatable wart from baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).

Time frame: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

Population: ITT population

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	No	8 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	No	10 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112	No	13 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	No	7 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	Yes - at least 1 wart reduction from Baseline	23 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112	Yes - at least 1 wart reduction from Baseline	17 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	Yes - at least 1 wart reduction from Baseline	22 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	Yes - at least 1 wart reduction from Baseline	20 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147 EOS	No	17 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147 EOS	Yes - at least 1 wart reduction from Baseline	13 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	No	11 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	Yes - at least 1 wart reduction from Baseline	19 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	Yes - at least 1 wart reduction from Baseline	6 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112	No	14 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147 EOS	Yes - at least 1 wart reduction from Baseline	8 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	Yes - at least 1 wart reduction from Baseline	10 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147 EOS	No	16 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	No	14 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	Yes - at least 1 wart reduction from Baseline	10 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	No	14 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	Yes - at least 1 wart reduction from Baseline	9 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	No	18 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	No	15 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112	Yes - at least 1 wart reduction from Baseline	10 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	Yes - at least 1 wart reduction from Baseline	21 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147 EOS	Yes - at least 1 wart reduction from Baseline	19 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	Yes - at least 1 wart reduction from Baseline	18 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112	No	9 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147 EOS	No	8 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112	Yes - at least 1 wart reduction from Baseline	18 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	No	9 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	Yes - at least 1 wart reduction from Baseline	17 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	No	6 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	No	4 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	No	10 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	Yes - at least 1 wart reduction from Baseline	23 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147 EOS	No	13 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	Yes - at least 1 wart reduction from Baseline	6 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 2	No	12 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	Yes - at least 1 wart reduction from Baseline	7 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	Yes - at least 1 wart reduction from Baseline	4 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 4	No	14 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	Yes - at least 1 wart reduction from Baseline	4 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Study Day 84 EOT Visit	No	14 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112	Yes - at least 1 wart reduction from Baseline	5 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 112	No	13 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	F/U Visit Day 147 EOS	Yes - at least 1 wart reduction from Baseline	5 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)	Treatment Visit 3	No	11 Participants

Comparison: Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0004Cochran-Mantel-Haenszel

Comparison: Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0005Cochran-Mantel-Haenszel

Comparison: Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0698Cochran-Mantel-Haenszel

Comparison: Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.p-value: 0.01Cochran-Mantel-Haenszel

Comparison: Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0101Cochran-Mantel-Haenszel

Comparison: Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0077Cochran-Mantel-Haenszel

Comparison: Study Day 84 EOT Visit: Part B summary is pooled with its respective treatments from Part A.p-value: 0.064Cochran-Mantel-Haenszel

Comparison: Study Day 84 EOT: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0045Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.284Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 112: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0132Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 147 EOS: Part B summary is pooled with its respective treatments from Part A.p-value: 0.4668Cochran-Mantel-Haenszel

Comparison: Follow-up Visit Day 147 EOS: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0064Cochran-Mantel-Haenszel

Other Pre-specified

Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)

Proportion of subjects who are clear at all three study visits, Study Day 84 (End of Treatment) Visit and remain clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study).

Time frame: Complete clearance compared from Day 84 to follow-up days 112 and 147.

Population: ITT Population

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)	Yes	5 Participants
Part B Pooled With Part A: VP-102 6-hour	Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)	No	25 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)	Yes	0 Participants
Part B Pooled With Part A: Placebo 6-hour	Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)	No	24 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)	Yes	7 Participants
Part B Pooled With Part A VP-102 24-hour	Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)	No	20 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)	No	18 Participants
Part B Pooled With Part A: Placebo 24-hour	Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)	Yes	0 Participants

Comparison: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0364Mantel Haenszel

Comparison: Part B summary is pooled with its respective treatments from Part A.p-value: 0.0215Cochran-Mantel-Haenszel

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Masking description

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Other

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.

Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)